Find Clinical Trials

Inclusion Criteria: * 19 to 65 years in age. * Parkinson's Group must have a physician dx of Parkinson's Disease * Must meet exhibit elevated levels of depression on the Beck Depression Inventory (scores of 20 or above). * Must be willing and able to travel of the Psychology Department for EEG and tDCS sessions. * Participants who have undergone surgery for Deep Brain Stimulation implantation may be enrolled if advised to and monitored by their physician. * Read and understand spoken English. Exclusion Criteria: * No history of or being treated for epilepsy or other seizure disorders. * No history of penetrating head wounds or TBI greater than mild TBI. * No history of atypical Parkinson's

Inclusion Criteria: * Pregnant and ≥28 weeks gestation * Attending ANC care at the facility * ≥14 years old * Screen positive for PMAD symptoms (PHQ-2≥3 and/or GAD-2≥3) * Willing to return to the MCH and PMTCT clinic for study visits Exclusion Criteria: * Less than 28 weeks gestation * Any woman at high risk of self-harm based on a study self-harm assessment protocol, * Has cognitive impairments or psychotic symptoms

Inclusion Criteria: 1. Type 2 diabetes 2. Adults 18 years or older 3. Written Informed Consent 4. HbA1c greater than or equal to 58 mmol/mol (7.5% DCCT standard) and less than 100 mmol/mol 5. Type 2 diabetes diagnosis \<4 weeks 6. Body mass index \> 25 kg/m2 Exclusion Criteria: 1. Pregnancy or planned pregnancy for the study duration 2. Type 1 diabetes 3. Judged to be in need of insulin 4. Severe cognitive dysfunction or other disease, which is judged by the physician to be not suitable for inclusion. 5. History of allergic reaction to chlorhexidine or alcohol anti-septic solution. 6. Abnormal skin at the anticipated glucose sensor attachment sites (excessive hair, burn, inflammation, infection, rash, and/or tattoo). 7. Participation in another study. 8. Other investigator-determined criteria unsuitable for patient participation.

Inclusion Criteria: Part 1: KAP on dietary salt and sugar intake 1. Students and staff of Sunway University and Sunway College aged 18 years and above 2. Able to provide informed consent (verbal/written) to participate 3. Understands English Part 2: KAP, Perception, Barriers and Enablers of Salt and Sugar Reduction among Campus Canteen Staff 1. Canteen staff that are involved in food preparation aged 18 years and above 2. Able to provide informed consent (verbal/written) to participate 3. Understands English Part 3: An interventional study for 6 months will expose them to foods sold on campus that have reduced salt and sugar. For intervention group 1. Individuals who eat on campus food for at least 3 meals per week 2. Consent to participate For control group 1. Individuals who do not eat on campus food or for less than 3 meals per week 2. Consent to participate Exclusion Criteria: 1\. Individuals with acute illness, psychological or psychiatric conditions

Inclusion Criteria: * Aged 18 years or older; * Meet DSM-5 criteria for major depressive disorder; * Presence of 1-3 negative future-oriented mental images, which cause distress; * Be able to understand questionnaires and study information letter; * In case of medication use: are stable on medication for six weeks or longer. Exclusion Criteria: * Current or history of psychotic disorder; * Current or history of bipolar disorder; * Severe cognitive impairment (e.g., mental retardation) as evidenced by educational records, parental report and/or clinical impression; * Current EMDR or imagery rescripting therapy; * Other circumstances that might affect participation (e.g., severe medical disorder, relocation).

Inclusion Criteria: * Physician-diagnosed T2DM * The history of T2DM less than 6 years * Most recent HbA1c higher than 6.5% * Body mass index: 24-45 kg/m2 * Fasting C-p ≥1.1 ng/ml * Inability to provide informed consent Exclusion Criteria: * Type 1 diabetes, type 2 diabetes currently treated with insulin, or HbA1c ≥12% * Cardiovascular events within 6 months before trial * Current use of anti-obesity medications, eating disorders, dieting behaviors, or weight loss \>5 kg within 6 months before trial * Chronic kidney disease stage 3b or above (eGFR \<30 mL/min/1.73m²) * Any condition causing fluid overload, such as heart failure or liver cirrhosis * Previously diagnosed psychiatric disorders (e.g., schizophrenia, post-traumatic stress disorder, obsessive-compulsive disorder), uncontrolled depression, or epilepsy * Severe arthritis or active gout * Active gallstone disease or known as asymptomatic gallstones * Concurrent enrollment in another clinical trial * Pregnancy, lactation, or planned conception during the study * Substance abuse * Known malignancy * Comorbidities increasing dietary intervention risk (e.g., biliary disorders) * Long-term use of antibiotics, corticosteroids, NSAIDs, or PPIs * Chronic gastrointestinal disorders affecting gut microbiota (e.g., ulcerative colitis) * Severe hepatic impairment (ALT \>2.5× ULN) * Inability to provide informed consent

Inclusion criteria 1. Signed Informed Consent 2. Males and females aged ≥18 years with a multi-system primary mitochondrial disease. 3. A confirmed mitochondrial DNA tRNALeu(UUR) m.3243A\>G mutation (m.3243A\>G PMD) plus an age adjusted heteroplasmy percentage ≥ 20% in white blood cells \[=blood heteroplasmy/0.977(age+12)\]. Or in urine (urinary epithelial cells), or buccal smear or skeletal muscle (results (obtained per local guidance) ≥ 20% must be available prior to the subject being randomized). 4. Presence of chronic fatigue (not attributable to other etiologies than PMD): 1. Patient self-reported chronic fatigue for at least 3 months prior to the Screening Visit and recorded in the clinical patient files; AND 2. Presence of fatigue (raw total score \>22), assessed by Neuro-QoL SFv1-F at Screening. 5. Presence of mitochondrial myopathy defined as: 5xSST at Screening and Baseline should be ≥ 11 seconds and participant must demonstrate the ability to complete the test at baseline (i.e., complete the test within 30 seconds). 6\. Other Inclusion criteria per protocol. Exclusion criteria 1. Treatment with any IMP within 3 months (or 5 times the half-life of the IMP, whichever is longer) prior to screening or plans to use an IMP (other than the study intervention) during the study. 2. Bone deformities, motor abnormalities or chronic ulcers that in the opinion of the PI may interfere with and/or confound the interpretation of the subject's performance during the 5 times sit to stand test (5XSST). 3. Surgery of gastrointestinal tract that might interfere with drug absorption. Or severe GI dysmotility, chronic vomiting, diarrhea, bouts of pseudo-obstruction which will impair appropriate IMP absorption in the opinion of the investigator. 4. Clinically significant respiratory disease and/or cardiac disease (medical history or current clinical findings) in the opinion of the investigator. 5. Prior interventional cardiac procedure (e.g., cardiac catheterization, angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to screening. 6. QTcF \> 450 msec (men) or QTcF \> 470 msec (women). 7. Structural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and/or abnormal conduction (QRS \>120 msec, PR \< 120 msec), and/or repolarization (QTcF \> 450 msec (men) or QTcF \> 470 msec (women)). Myocardial function (LVEF \<52% in men and \< 54% in women), symptomatic ischemic heart disease (inducible ischemia or coronary obstruction), and/or pathologic hypertrophy (e.g. \> 15mm septal or posterior wall thickness), that is not well controlled under current specialized care. Subjects with congestive heart failure class II and above should also be excluded. 8. Family history of unexplained/uninvestigated syncope or congenital long and short QT syndrome or sudden death (under the age of 60). ECG evidence of acute or recent ischemia, acute or Recent Myocardial Infraction, atrial fibrillation, high grade AV Blocks (Second Degree AV Block Type II or Third-degree AV Block), complete Heart Block or active conduction system abnormalities with the exception of any of the following: 1. First degree atrioventricular (AV)-block 2. Second degree AV-block Type 1 (Mobitz Type 1/Wenckebach type) 3. Right bundle branch block. 9. History of acute heart failure (within the last 3 months). 10. Higher degree of AV-blocks (AVB II° or III°). 11. Other exclusion criteria per protocol

Inclusion Criteria: 1. A clear histopathologic diagnosis of breast cancer with HER2-negative subtype (including IHC 0, IHC 1+ or IHC 2+ and ISH negative); 2. Cerebrospinal fluid cytology confirms the presence of leptomeningeal metastases; or imaging findings combined with clinical symptoms and signs are consistent with the diagnosis of leptomeningeal metastases; 3. Age ≥ 18 years old. Exclusion Criteria: 1. Inadequate organ function: 1) Blood tests: ANC ≤ 1.5 x 10\^9/L, PLT ≤ 90 x 10\^9/L, Hb ≤ 90 g/L; 2) Blood biochemistry tests: TBIL ≥ 1.5 times the upper limit of normal; 3) ALT and AST ≥ 2.5 times the upper limit of normal; 2. Presence of serious and/or uncontrolled comorbidities that may affect participation: 1) Allergy to study drugs or adjuvant materials; 2) History of immunodeficiency (e.g., HIV-positive or other acquired or congenital immunodeficiency disease); 3) Severe concomitant diseases; 3. Pregnant and breastfeeding female patients; women of childbearing age who are unwilling or unable to use effective contraception; 4. Any other condition that, in the opinion of the investigator, makes the patient ineligible for participation in the study.

Inclusion: * Both sexes; * Ages between 18 and 65 years old; * Diagnosis of Major Depressive Disorder (MDD) made by a clinician according to Diagnostic Statistical Manual criteria-5-Text Revised (DSM-5-TR) * Patients with Hamilton Depressive Rating Scale-17 items (HDRS-17) scores 14-23; * Informed and signed consent form. Exclusion: * Unstable serious clinical or neurological diseases; * Postpartum depression or other types of depressive disorders (disruptive mood dysregulation disorder, pre-menstrual, substance/medication-induced depressive disorder, depressive disorder due to another medical condition, another disorder specified depressive disorder and unspecified depressive disorder); * Other psychiatric disorders; * Patients with active psychotic symptoms; * Suicidality risks * Patients already undergoing any other psychological treatment for MDD; Discontinuation: * More than two absences during treatment; * Those who miss more than two sessions/consultations, whether medical treatment or the psychoeducational program; * Non-response to the use of Sertraline over the initial eight weeks; Presence of hypomanic symptoms at any time during treatment (Young \&lt;7)

Inclusion Criteria: 1. Between 18-65 years of age, at the time of informed consent. 2. Body Mass Index (BMI) between 30-50 kg/m2 3. Meets one of the following criteria: 1. Type 2 Diabetes Mellitus (T2DM; defined as HbA1c ≥ 6.5%) or weight regain following previous sleeve gastrectomy (≥ 12 months); OR 2. Type 2 Diabetes Mellitus (T2DM; defined as HbA1c ≥ 6.5%) or weight regain following previous endoscopic sleeve gastroplasty (≥ 12 months); OR 3. Type 2 Diabetes Mellitus (defined as HbA1c ≥ 6.5%) with a Body Mass Index between 30-35 and without previous sleeve gastrectomy and no plan to perform a concurrent sleeve gastrectomy. 4. Participant agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for the duration of the study. 5. Participant has been informed of the nature of the study and agrees to its provisions, complying with study required testing, medications, follow-up visits, and has provided written informed consent. Exclusion Criteria: 1. Type 1 diabetes. 2. Use of injectable insulin. 3. Uncontrolled Type 2 Diabetes Mellitus (T2DM). 4. Investigator plans to perform a sleeve gastrectomy with the duodeno-ileal anastomosis procedure. 5. Uncontrolled hypertension, dyslipidemia or sleep apnea. 6. Prior intestinal, colonic or duodenal surgery (other than bariatric). 7. Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the procedure, including scarring and abnormal anatomy. 8. Refractory gastro-esophageal reflux disease (GERD). 9. Barrett's disease. 10. Helicobacter pylori positive and/or active ulcer disease. 11. Large hiatal hernia. 12. Inflammatory bowel or colonic diverticulitis disease. 13. Any anomaly precluding orogastric access by gastroscope and catheters, and manipulation techniques. 14. Any anomaly preventing / contraindicating endoscopic or laparoscopic access and procedures. 15. Implantable pacemaker or defibrillator. 16. Psychiatric disorder, except well-controlled depression with medication for \> 6 months. 17. History of substance abuse. 18. Pregnant, lactating, or planning pregnancy during the clinical investigation. Note: Female participants of childbearing age must agree to use safe contraception (e.g., intrauterine devices, hormonal contraceptives: contraceptive pills, implants, transdermal patches hormonal vaginal devices, injections with prolonged release). 19. Any comorbidity or current status of participant's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the participant medically unfit for the procedure, including any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the Magnets. 20. Unhealed ulcers, bleeding lesions, tumor, or any other lesion at target Magnet deployment site. 21. Expected need for Magnetic Resonance Imaging (MRI) within the first 2 months post-procedure. 22. Any surgical or interventional procedure (including planned and/or scheduled) within the period of 30 days prior to and 30 days following the study procedure. 23. Any stroke / Transient Ischemic Attack (TIA) 6 months prior to consent. 24. Requires chronic anticoagulation therapy (except aspirin). 25. Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure. 26. Recent tobacco or nicotine product cessation 3 months prior to informed consent. 27. Known allergies to the device components (including the biofragmentable material PGLA or similar compounds) or contrast media. 28. Participants with comorbidities that are likely to result in a life expectancy of 12 months. 29. Currently participating in an investigational drug or another device study that has not reached its primary endpoint: Note: Studies requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. 30. A positive COVID-19 test prior to the study procedure in accordance with local COVID-19 protocol. 31. Presence of other anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.

Inclusion Criteria: * Patient aged 18 and over, included in the MESANTIDEP study for whom SSRI ( Selective serotonin reuptake inhibitor) treatment is planned. * Patient who has received full information on the organization of the research and has given written informed consent (or a third person, independent of the investigator and sponsor, in the event of inability to read or write), * Patient affiliated to a social security scheme or beneficiary of such a scheme Exclusion Criteria: * Contraindications for 18F-FDG PET/CT scans * Presence of chronic neurological or psychiatric pathologies pre-Covid-19

Inclusion Criteria: 1, Aged ≥ 21 2. Diagnosis of: * early-stage breast cancer at low risk of recurrence * defined as clinical stage 1 or 2 * completed primary treatment (surgery, chemotherapy \[adjuvant, patients may continue to be treated with neoadjuvant\], and/or radiation) \> 6 months ago * oncologist reported risk of recurrence at 10 years \< 20% * late-stage ovarian cancer at high risk of recurrence * defined as Clinical stage 3 or 4 * currently in remission * oncologist reported risk of recurrence at 10 years \> 80% 2. Functional Status defined as: * Eastern Cooperative Oncology Group (ECOG) ≤1 * Palliative Performance Scale (PPS) ≥60% * Ability to tolerate PO medication administration 4. Fear of recurrence at screening and baseline 5. Have an identified support person * Agree to be accompanied home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing 6. Participants of childbearing potential must agree to practice an effective means of birth control throughout the duration of the study. Exclusion Criteria: 1. Unstable medical conditions or serious abnormalities of complete blood count, chemistries, or EKG that in the opinion of the study physician would preclude safe participation in the trial. Some examples include: * Congestive heart failure * Valvular heart disease * Clinically significant arrhythmias (e.g., ventricular fibrillation, torsades) or clinically significant EKG abnormality (i.e., QTC interval \> 450) * Recent acute myocardial infarction or evidence of ischemia * Malignant hypertension * Congenital long QT syndrome * Acute renal failure * Severe hepatic impairment * Respiratory failure * eGFR \< 50 mL/min/1.73m2 * LFTs \> 1.5 x ULN * WBC \< 5 x 10\*9/L * Hemoglobin \< 8.0 g/dL * Platelets \< 150 x 10\*9/L 2. Risk for hypertensive crisis defined as: Screening and Baseline blood pressure \>140/90 mmHg 3. Significant central nervous system (CNS) pathology Examples include: * Primary or secondary cerebral neoplasm * Epilepsy * History of stroke * Cerebral aneurysm * Dementia * Delirium 4. Primary psychotic or affective psychotic disorders Examples include current or past DSM-5 criteria for: * Schizophrenia spectrum disorders * Schizoaffective disorder * Bipolar I or bipolar II disorder * Major Depressive Disorder with psychotic features * Prior history of psychosis due to medical condition or substance use 5. Family history of psychotic or serious bipolar spectrum illnesses. Examples include first-degree relative with: * Schizophrenia spectrum disorders * Schizoaffective disorder * Bipolar I disorder with psychotic features 6. High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation and judgement. Examples include: * Agitation * Violent behavior 7. Active substance use disorders (SUDs) defined as: * DSM-5 criteria for moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine) within the past year * DAST-10 score of 3 or higher * Two or more "yes" responses to CAGE screening questionnaire 8. Extensive use of serotonergic hallucinogens (e.g., LSD, psilocybin) defined as: * Any use in the last 12 months * \>25 lifetime uses 9. Clinically significant suicidality or high risk of completed suicide defined as: * 'Yes' to C-SSRS Suicidal Ideation items 4 or 5 within the last 2 months at Screening or 'since last visit' at Baseline * Any C-SSRS Suicidal Behavior item within the past 12 months at Screening or 'since last visit' at Baseline, as defined by 'Yes' to any of the following on the C-SSRS: actual attempt, interrupted attempt, aborted attempt, or preparatory acts * Have any suicidal ideation or thoughts, in the opinion of the study physician or PI, that presents a serious risk of suicidal or self-injurious behavior 10. History of hallucinogen persisting perception disorder (HPPD) 11. Pregnancy/lactation 12. Cognitive impairment as defined by: • Montreal Cognitive Assessment Test (MoCA) \< 23 13. Concurrent Medications * Antidepressants * Centrally-acting serotonergic agents (e.g., MAO inhibitors) * Serotonin-acting dietary supplements (such as 5-hydroxy-tryptophan or St. John's wort) * Antipsychotics (e.g., first and second generation) * Mood stabilizers (e.g., lithium, valproic acid) * Aldehyde dehydrogenase inhibitors (e.g., disulfiram) * Significant inhibitors of UGT 1A0 or UGT 1A10 * Efavirenz 14. Have a positive urine drug test including Amphetamines, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Cannabis, Methamphetamine, MDMA, Methadone, Opiates (Morphine, Oxycodone) unless prescribed, and Phencyclidine (PCP). 15. Have a psychiatric condition judged to be incompatible with establishment of rapport with the study therapists or safe exposure to psilocybin 16. Have any psychological or physical symptom, medication, or other relevant finding , based on the clinical judgment of the PI or relevant clinical study staff that would make a participant unsuitable for the study. 17. Have an allergy or intolerance to any of the materials contained in the drug product 18. Non-English speaking individual 19. Be enrolled in another clinical trial assessing intervention(s) for anxiety, depression, and/or existential distress (e.g., pharmacologic or psychotherapeutic interventions)

Inclusion Criteria: Cohort 1: * BC patients, male and female, * 18 years old and older, * Pre or post menopausal, * With HR+ (ER and/or PR positive) and Her-2 negative (confirmed centrally), * Locally advanced irresectable and/or metastatic disease * Confirmation of HR and Her-2 status may be performed in the primary tumor or in the metastatic lesion (patients with discordant results may be included), * Patients must be candidates to CDK4/6i therapy in combination with endocrine therapy in the first line setting (with or without ovarian suppression) * Patients may have received one previous line of chemotherapy in the metastatic setting, but no endocrine therapy in the metastatic setting is allowed, * Patients may have received chemotherapy in the neo/adjuvant setting, * Patients may have received endocrine therapy (with or without ovarian suppression) in the neo/adjuvant setting, * Patients may have received a CDK4/6i in the adjuvant setting, provided they are still candidates for CDK4/6i therapy in the metastatic setting, * Patients must be able to undergo a liquid biopsy procedure before starting their first line treatment, * All patients must fill and sign an informed consent form. Cohort 2: * BC patients, * Male and female, * 18 years old and older, * pre or post menopausal, * With HR+ (ER and/or PR positive) and Her-2 negative (confirmed centrally), * Locally advanced irresectable and/or metastatic disease who have progressed on a CDK4/6i in combination with endocrine therapy (with or without ovarian suppression) in the first or second line setting, * All other non-conflicting inclusion criteria for cohort 1 apply. Cohort 3: * BC Patients, * Male and female, * 18 years or older, * pre- or post-menopausal, * With HR+ (ER and/or PR positive), HER2-negative (centrally confirmed) locally advanced unresectable and/or metastatic disease, * Confirmation of HR and HER2 status may be performed on the primary tumour or the metastatic lesion (patients with discordant results may be included), * Patients must be on first-line hormonal therapy with an aromatase inhibitor plus a CDK4/6 inhibitor (with or without ovarian suppression) for at least 6 months, * No clinical or radiological evidence of progressive disease, * Patients may have received a prior line of chemotherapy in the metastatic setting; however, prior endocrine therapy in the metastatic setting is not permitted, * Patients may have received chemotherapy in the neoadjuvant/adjuvant setting, * Patients may have received endocrine therapy (with or without ovarian suppression) in the neoadjuvant/adjuvant setting, * Patients may have received a CDK4/6 inhibitor in the adjuvant setting, provided they are still eligible for CDK4/6 inhibitor therapy in the metastatic setting, * Patients must be able to undergo a liquid biopsy procedure before starting their first-line treatment, * All patients must read and sign an Informed Consent Form. Exclusion Criteria: * Patients WITHOUT HR+ (ER- and/or PR-positive)/HER2-negative disease, * Patients without radiological and/or pathological confirmation of locally unresectable and/or metastatic breast cancer, * Patients who are NOT candidates for further systemic treatment following a diagnosis of metastatic disease or disease progression, * Patients who have already started a CDK4/6 inhibitor in combination with endocrine therapy (with or without ovarian suppression) for first-line metastatic disease (for Cohort 1); * Patients who have already started a new line of treatment for metastatic disease following progression on a CDK4/6 inhibitor in combination with endocrine therapy (with or without ovarian suppression) (for Cohort 2); * Patients with any suspicion of clinical or radiological disease progression at the time of the first liquid biopsy collection (for Cohort 3), * Patients who are NOT able to undergo a liquid biopsy procedure, * Patients who are NOT able to provide informed consent.

Inclusion Criteria: * Participants must meet the diagnostic criteria for MDD as outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). * Participants must have a baseline score of 18 or higher on the 24-item Hamilton Depression Rating Scale (HDRS-24). * During the trial's treatment period, participants must be using a single antidepressant medication at a stable dose. * Participants must be between the ages of 18 and 65 years. * Informed consent from both parents and legal guardians is required. Exclusion Criteria: * Individuals with current or history of organic brain disorders or neurological disorders will be excluded from the study. * Participants with a Wechsler Abbreviated Scale of Intelligence (WASI) score of less than 70 will be excluded. * Individuals currently taking antiepileptic drugs, benzodiazepines, or other medications that may affect seizure activity will be excluded from the study. * Those with exposure to ECT, modified ECT, MST, transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neurostimulation treatments in last 6 months will be excluded. * Individuals with cochlear implants, cardiac pacemakers, implanted devices, or metal in the brain will be excluded from participation. * Pregnant or lactating individuals will be excluded from the study. * Individuals currently participating in another concurrent clinical trial will not be eligible for inclusion. * Participants who refuse to provide informed consent to participate in the trial will be excluded. * Other circumstances deemed unsuitable for participation by researchers will result in exclusion.

Inclusion Criteria: * Self-identify as either non-Hispanic Black or non-Hispanic White. * Men and women 18-75 years old. * Non-hypertensive (systolic blood pressure \[SBP\]\<130 and diastolic blood pressure \[DBP\] \<85 mmHg). * Have low density lipoprotein cholesterol \<150mg/dl. * Have HbA1C \<6.0%. Exclusion Criteria: * Rash, skin disease, or disorders of pigmentation (e.g., psoriasis, eczema, vitiligo, or other skin inflammatory skin disorders) * Known skin allergies to latex or adhesives * Smoking and/or use of nicotine-containing products within the past year * Use of illegal/recreational drugs * Generalized kidney disease * Taking chloramphenicol, cholestyramine, medication for seizures, methotrexate, nitrofurantoin, tetracycline, barbiturates, steroids, phenobarbital/phenytoin, orlistat or pyrimethamine * Any current medications which could conceivably alter the cardiovascular control or responses * Diagnosed or suspected metabolic or cardiovascular disease * Current pregnancy or breastfeeding * History of skin or other cancers * Diagnosed or suspected diabetes (HbA1c ≥6.0) * Anybody with narcolepsy or who has been diagnosed with any condition that impairs body temperature regulation.

Inclusion Criteria: * Adult asthma patients with a scheduled consultation at the outpatient hospital to whom a step-up or step-down of their pharmacological asthma treatment is prescribed Exclusion Criteria: * Unstable asthma (defined as need for oral corticosteroids or (respiratory) antibiotic course in the 4 weeks before inclusion or any major medical issue in the 4 weeks before inclusion)

Inclusion Criteria: * Ability to understand and willing to provide written informed consent and to comply with scheduled visits and study procedures; * Female, aged 18 to 70 years (inclusive); * Histologically confirmed unresectable locally advanced or metastatic breast cancer with negative status for ER, PR, and HER-2. Testing results for all three markers conducted within 24 months prior to the initiation of the study by a local facility accredited by clinical research center are acceptable. If deemed necessary by the investigator during screening, subjects may provide additional biopsy to confirm the latest pathological; * Subjects who have not received prior systemic treatment（except endocrine therapy） for advanced breast cancer are eligible for the study. Subjects who have received Taxane-based chemotherapy during the neoadjuvant and/or adjuvant treatment phase are eligible, as long as the occurrence of relapse or metastasis is at least 12 months after the end of treatment; * Performance status as assessed by the Eastern Cooperative Oncology Group (ECOG) is 0-1; * Life expectancy of 12 weeks or more; * According to RECIST 1.1, the subject has at least 1 measurable lesion as the targeted lesion (the only bone metastasis or the only central nervous system metastasis should not be considered as a measurable lesion. A measurable lesion located at the previously irradiated radiation field or other local treatment area should not be selected as targeted lesion, unless the lesion shows unequivocal radiographic progression). Exclusion Criteria: * Previous treatment with immune checkpoint agonists (such as CD137 agonists) or immune checkpoint inhibitors (such as CTLA-4, PD-1, PD-L1, LAG3 monoclonal antibody, etc.) or anti-vascular endothelial growth factor (VEGF) target drugs; * Has uncontrolled or symptomatic brain or spine cord metastases; * Those who have had other active malignant tumors within 5 years prior to the study treatment, except for those that can be treated locally and have been cured ; * Poorly controlled hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg); * With a history of hypertensive crisis or hypertensive encephalopathy; * With a history of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 6 months prior to the start of the study treatment; * Adverse events resulting from prior anti-tumor therapies should be assessed and graded according to the CTCAE 5.0 criteria, subjects whose AEs have not returned to Grade 1 or below; * Has uncontrollable pleural, pericardial, or abdominal effusions; * Has received allogeneic hematopoietic stem cell transplantation or organ transplantation.

Inclusion Criteria: 1. Severe asthma patients aged 19 or older and 79 or younger 2. Cases diagnosed as asthma by an expert and classified as severe asthma according to the 2014 ATS/ERS guidelines \- Patients who require the use of high-dose inhaled steroids and additional control agents or systemic steroids for more than 50% of the year to control symptoms. Or, if asthma is not controlled even with the medication. Here, uncontrolled asthma means that any one of the following is satisfied. 1. ACT score less than 20 or 'not well controlled' according to GINA guideline 2. frequent exacerbations; Requires systemic steroid administration (over 3 consecutive days) more than twice in the previous year If you did 3. severe exacerbation; A condition that required hospitalization, admission to an intensive care unit, or application of a ventilator in the previous year If you have been angry at least once 4. airflow restrictions; FEV1 \< 80% 3. If a cough is due to asthma according to a doctor and the cough onset scale (cough visual analogue scale, cough VAS) satisfies 30 or more points out of 100. 4. If a positive result is confirmed in the methacholine (or mannitol) bronchial challenge test (if the bronchial challenge test result is not available or the test is difficult to proceed, it can be replaced with a positive bronchodilator response test) Exclusion Criteria: 1. Minors under 19 years of age, senior citizens over 79 years of age 2. If there is a history of use of other biological agents within 3 months prior to study registration 3. Cases where there was an acute exacerbation requiring a steroid burst (total 90mg prednisolone or more) during the 4-week screening period before study registration (possible for long-term prednisolone users) 4. Cases accompanied by clinically serious respiratory disease in addition to severe asthma 5. When accompanied by hypereosinophilic syndrome, ABPA, EGPA 6. When it is difficult to evaluate asthma alone due to severe respiratory disease 7. Pregnant women

Inclusion Criteria: * provide unpaid care to a person diagnosed with early to moderate stage dementia; * provide at least 14 hours of care a week for at least 3 months * aged 18 years or above * able to read * have depressive symptoms * use a message application Exclusion Criteria: * with an unstable physical or mental condition * with cognitive impairment * receiving medical, psychological, or psychiatric treatment for depression * have been included in another interventional study

Inclusion Criteria: * Being a male or female patient with asthma who is between 20 and 65 years old. * Being a patient who has been diagnosed by a doctor with asthma for at least 6 months. * The severity of the disease has been assessed at levels 2 to 4, meaning the volume of air expelled in the first second of breathing quickly and with full force (Forced Expiratory Volume in one second; FEV1) is between 80% and 30% on the date of data collection. This has been certified by a doctor, and the patient is using medication according to the normal treatment plan. * Must not have other respiratory diseases such as tuberculosis, lung cancer, emphysema, chronic obstructive pulmonary disease (COPD), etc. * Should not have received exercise training for more than 20 minutes at a time, 3 days/week, or more in the past 6 months before participating in the research. * Having no communication problems. * The sample volunteers to participate in the research and agrees to sign the consent form to participate in the research. Exclusion Criteria: * Being a patient who has a history of asthma caused by exercise (Exercise-Induced Asthma). * In case of a force majeure event that makes it impossible to continue participating in the research, such as injury from an accident or illness, etc. * Participating in less than 80 percent of the training sessions (28 times out of 36 times) for the breathing training group and the group that practiced breathing together with massage. * Unwillingness to continue participating in the research.